Sonnet BioTherapeutics Holdings, Inc.

of this Current Report on Form 8-K is incorporated by reference into this Item 5.02. In connection with the Business Combination and pursuant to the terms of th

Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing. The information set forth in the Explanatory Note and under

Unregistered Sales of Equity Securities. The information set forth in in the Explanatory Note and Item 2.01 relating to the Closing PIPE is incorporated by refe

Material Modification to Rights of Security Holders. The information set forth in the Explanatory Note and under Item 2.01, Item 3.01, Item 5.01, Item 5.02 and

. As a result of the Business Combination, a change in control of Sonnet occurred, and Sonnet is now a wholly owned subsidiary of HSI. Item 5.02 Departure of Di

Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year. On the Closing Date, Sonnet filed a Certificate of Amendment to Sonnet’s Certificate o

Submission of Matters to a Vote of Security Holders. On December 2, 2025, Sonnet held its special meeting of stockholders (the “Special Meeting”). The matters v

Regulation FD Disclosure. On Closing Date, Sonnet and HSI issued a joint press release announcing the Closing. A copy of the press release is attached hereto as

Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 2.1* Business Combination Agreement. 2.2 Amendment No. 1 to Business Combination Agreem